Browse more cannabis research, findings, methods, and limitations.
Rats pre-exposed to nicotine became more sensitive to THC reward at low doses and experienced worse withdrawal, suggesting nicotine primes the brain for cannabis effects.
A study tracking teens from age 13 to 25 found early-onset escalating cannabis users had 8x higher odds of cannabis use disorder and 3x higher depression risk.
A mouse study found targeting both CB2 and TRPV1 receptors reduced osteoarthritis pain and inflammation more effectively than either target alone.
A review of 328 facial trauma patients found cannabis users had more severe injuries but similar surgical outcomes compared to non-users.
A study of 11,569 adults found higher dispensary density near homes was linked to more frequent cannabis use among users, but not to whether someone used at all.
A survey of 237 oncologists found 68% believed cannabis could benefit patients, but only 23% felt knowledgeable and 15% had formal training.
A review of 142 pediatric medical cannabis patients found 73% parent satisfaction, with epilepsy patients showing the most measurable benefit (34% seizure reduction >50%).
An observational study of 50 autistic children found 60% improved with CBD-rich cannabis oil, with aggression and self-injury showing the most benefit.
BC poison control data showed cannabis calls for children under 10 doubled after legalization, with edibles involved in 72% of post-legalization pediatric cases.
An analysis of 1.2 million CUD treatment episodes found Black patients received evidence-based therapy at half the rate of White patients, even after controlling for insurance and severity.
A survey of 3,200 parents found children exposed to secondhand cannabis smoke had 2.1x higher wheezing risk and 1.8x higher nighttime cough risk.
A study of 412 young adults found cannabis use was associated with paranoid thinking only in those with a history of childhood trauma, not in those without.
A preclinical review suggests partial dopamine agonists like cariprazine could treat both schizophrenia and cannabis addiction by stabilizing dopamine signaling.
An expert review identifies specific developmental windows when the brain's CB1 receptor system makes youth vulnerable to lasting effects from cannabis.
College students with type 1 diabetes: 41% used marijuana, with grit and illness acceptance protective while depression increased risk.
Aged rats treated with cannabis showed hippocampal characteristics resembling young adults, with reduced neuroinflammation and no motor impairment.
CBC and CBG killed glioblastoma cells in vitro, identifying GPR55 and PINK1 as potential therapeutic targets.
Six weeks of HIIT reduced CB1 receptors across brain regions in rats, with sex differences in baseline and cerebellar response.
The endocannabinoid system is present throughout urinary and reproductive tissues, with therapeutic potential for bladder disorders.
A healthy 32-year-old had a heart attack requiring emergency stent placement after smoking synthetic cannabinoid Mojo.
A young man with no cardiac risk factors developed Wellens syndrome linked to cannabis smoking.
NSAIDs, paracetamol, and other common painkillers enhance endocannabinoid levels and interact with cannabinoid signaling.
Cannabis smoke plus seed oil diet weakened heart function, suppressed anti-inflammatory mediators, and increased immune activation in mice.
CBD may protect the cardiovascular system through anti-inflammatory and vasoprotective effects, with early trials showing blood pressure reduction.
CBD and CB2 activation promote bone healing; chronic THC linked to 1.8-3.6x higher spinal fusion failure.
Blocking FABP5 prevented stress-induced anxiety and depression in rats while preserving hippocampal neurogenesis.
Synthetic cannabinoids reduced inflammation in prefrontal cortex but increased it in hippocampus, with withdrawal triggering further changes.
Medical cannabis patients used cannabis during pregnancy for symptoms and while parenting for stress, despite significant stigma.
A 15-year French survey of 150,000+ teens found that while fewer adolescents use cannabis today, those who do show much stronger associations with suicidal thoughts and antidepressant use than teen users did in 2008.
Two elderly patients with advanced liver cancer experienced complete tumor regression after taking cannabis oil for symptom relief — remarkable but uncontrolled case reports that highlight the need for clinical trials.
An analysis of 8 million+ alcohol screenings in California found that cannabis legalization was associated with declining heavy drinking in younger adults (21–34) but not in older adults, suggesting age shapes the substitution effect.
THC reversed HIV-induced premature aging of brain support cells and reduced inflammatory signaling in a primate model, suggesting cannabinoids may help protect the brain during chronic HIV infection.
Both high-CBD and high-THC cannabis reduced insulin resistance and liver disease in obese mice while shifting inflammatory immune cells toward a less harmful profile.
A Michigan pregnancy cohort of 584 women found that the 15% who used cannabis during pregnancy had babies with significantly smaller birth size, supporting guidelines advising against prenatal cannabis use.
A study of 420,000+ matched patients found cannabis users had significantly higher rates of every type of arrhythmia studied, with the strongest association for dangerous ventricular arrhythmias (nearly 3× the risk).
An experiment with 1,402 California teens found that micro-influencer posts combining cannabis and e-cigarette marketing increased teens' intentions to try e-cigarettes, especially when influencers were perceived as credible.
A JAMA-published study of 4,232 California teens found that frequent exposure to cannabis and e-cigarette social media posts predicted actual substance use initiation over one year, with friend and influencer posts showing the strongest links.
Overactive CB1 cannabinoid receptors were found in Down syndrome brains, and blocking these receptors with rimonabant improved memory and reduced neuroinflammation in a DS mouse model.
A meta-analysis of polysomnographic studies found cannabis doesn't consistently change measurable sleep patterns, but quitting after regular use clearly disrupts sleep — highlighting a gap between subjective and objective sleep effects.
Brief stress before adolescent binge drinking protected rats from memory damage by restoring endocannabinoid system gene expression that alcohol had disrupted in the hippocampus.
CBD reduced seizures and extended survival in mice with a rare childhood epilepsy (DEE1), working through anti-inflammatory pathways and ion channel modulation.
Among NYC adults over 50 with cannabis history, housing instability was linked to worse health and higher substance use, suggesting aging-in-place programs should integrate financial and substance use support.
Among 1,322 Canadian adults with type 1 diabetes, cannabis users had 58% higher odds of poor sleep quality — notable given that nearly half of T1D adults already sleep poorly.
A study of 27 cancer survivors found CBD (up to 300 mg/day) improved nerve damage symptoms, and adding exercise further enhanced pain relief, mobility, and quality of life over 4 months.
A review finds cannabinoids help cancer patients tolerate immunotherapy side effects but may reduce its anti-cancer effectiveness through CB2-mediated immunosuppression — recommending CBD/CBG over THC during treatment.
CBD (Epidiolex) reduced seizures in 67% of 27 patients with Rett syndrome or CDKL5 deficiency, with caregivers reporting improvements in attention, sleep, and motor function over 14 months.
Synthetic cannabinoids reduced brain inflammation markers in aging mice by targeting CB1 and CB2 receptors, and the endocannabinoid system naturally increased its expression with age.
Legal CBD products with trace THC caused positive oral fluid drug tests in up to 80% of participants, and even pure CBD products produced some false positives due to analytical conversion during testing.
A global ILAE survey of 86 countries found that even where CBD is approved for epilepsy, most countries report it unaffordable (72%) and hard to access (56%), while unregulated products fill the gap worldwide.
A pilot RCT found that a digital education program significantly increased oncology nurses' intention to support safe cannabis use in young adult cancer patients, with 89% completion rates.